Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Genscript Biotech Corporation

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

VOLUNTARY ANNOUNCEMENT
UNUSUAL PRICE MOVEMENT

This announcement is made by Genscript Biotech Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") has noted the recent unusual movements in the price of the shares of the Company (the "**Shares**"). The Board wishes to provide the shareholders of the Company (the "**Shareholders**") and potential investors with the following information.

Reference is made to the announcement of the Company dated 21 September 2026 regarding the change in board lot size of the Company from 2,000 Shares to 1,000 Shares (the "**Previous Announcement**"). The Company has noted that certain financial media have extracted information from the Previous Announcement and have disseminated messages suggesting that the Company will close its trading counter, which may cause misunderstanding among investors. The Company kindly reminds the Shareholders and potential investors of the Company that the temporary counter for trading in the Shares in board lots of 2,000 Shares will close on 4:10 p.m. Wednesday, 4 November 2026. The timetable for the change in board lot size (which is identical to that disclosed in the Previous Announcement) is set out below, where all times and dates refer to Hong Kong local times and dates:

Event	**Time and date**
Publication of this announcement on the Change in Board Lot Size	Monday, 21 September 2026
First day for free exchange of the existing share certificates in board lots of 2,000 Shares for the new share certificates in board lots of 1,000 Shares	Tuesday, 29 September 2026
Last day for trading in the Shares in board lots of 2,000 Shares in the original counter	Tuesday, 13 October 2026

Effective date of the Change in Board Lot Size ..... Wednesday, 14 October 2026

Original counter for trading in the Shares in board lots of 2,000 Shares becomes counter for trading in the Shares in board lots of 1,000 Shares ..... 9:00 a.m. Wednesday, 14 October 2026

Temporary counter for trading in the Shares in board lots of 2,000 Shares opens ..... 9:00 a.m. Wednesday, 14 October 2026

First day of parallel trading in the Shares (in board lots of 1,000 Shares and 2,000 Shares) ..... 9:00 a.m. Wednesday, 14 October 2026

Temporary counter for trading in the Shares in board lots of 2,000 Shares closes ..... 4:10 p.m. Wednesday, 4 November 2026

Last day of parallel trading in the Shares (in board lots of 1,000 Shares and 2,000 Shares) ..... 4:10 p.m. Wednesday, 4 November 2026

Last day for free exchange of the existing share certificates in board lots of 2,000 Shares for the new share certificates in board lots of 1,000 Shares ..... 4:30 p.m. Friday, 6 November 2026

Recently, the Company successfully held its 2026 investor day event on 30 October 2026. The business and operations of the Group remain normal, and there is no material change in the business management and financial position of the Group.

Having made such enquiries with respect to the Company as are reasonable in the circumstances, the Board confirms that, save as disclosed in this announcement, as of the time of this announcement, it is not aware of any reasons for the movements in the price of the Shares, nor is it aware of any inside information that needs to be disclosed under Part XIVA of the SFO.

The Shareholders and potential investors of the Company are advised to carefully consider all relevant investment information and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 3 November 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng ("**Mr. Robin Meng**"), Dr. Fangliang Zhang ("**Dr. Frank Zhang**"), Dr. Li Zhu and Ms. Ye Wang ("**Ms. Sally Wang**"); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung ("**Mr. Andy Cheung**"), Mr. Jiuan Pan ("**Mr. Ethan Pan**"), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi ("**Dr. Victor Shi**").*